AstraZeneca: Alexion Data at AAN 2024 Demonstrate How ULTOMIRIS and SOLIRIS Can Transform Outcomes for Rare Neurological Diseases
April 09, 2024
April 09, 2024
WILMINGTON, Delaware, April 9 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
Alexion, AstraZeneca Rare Disease, will present new clinical and real-world data from its leading rare neurology portfolio at the American Academy of Neurology (AAN) Annual Meeting in Denver, CO, April 13 to 18, 2024. The company will present 14 abstracts, including five oral presentations, across both generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum dis . . .
Alexion, AstraZeneca Rare Disease, will present new clinical and real-world data from its leading rare neurology portfolio at the American Academy of Neurology (AAN) Annual Meeting in Denver, CO, April 13 to 18, 2024. The company will present 14 abstracts, including five oral presentations, across both generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum dis . . .